东宝生物 (300239.SZ) Financial Statements

Income statement

Metric	TTM	2025	2024	2023	2022
Revenue
Total Revenue	747.8M	745.3M	884.9M	974.5M	943.4M
Cost of Revenue	574.6M	571.2M	683.9M	725.7M	710.0M
Gross Profit	173.2M	174.1M	201.1M	248.8M	233.4M
Operating Expenses
R&D Expense	25.0M	25.5M	27.4M	26.1M	25.8M
SG&A Expense	—	—	—	—	—
General & Admin Expense	49.2M	51.2M	50.0M	51.5M	51.2M
Selling & Marketing Expense	19.9M	19.0M	18.7M	19.6M	17.8M
Other Expenses	—	—	—	—	—
Total Operating Expenses	107.5M	108.3M	100.4M	108.6M	109.6M
Cost and Expenses	682.1M	679.5M	784.3M	834.3M	819.6M
Operating Income (EBIT)	60.0M	59.7M	106.2M	143.9M	130.5M
Non-Operating
Interest Income	—	—	—	—	—
Interest Expense	—	—	—	—	—
Net Interest Income	—	—	—	—	—
Other Non-Op Income/Expense	—	—	—	—	—
Non-Operating Income (excl Interest)	—	—	—	—	—
EBT (Pre-Tax Income)	62.6M	61.9M	105.6M	144.5M	131.6M
Income Tax Expense	7.6M	7.6M	14.4M	17.1M	16.2M
Bottom Line
Net Income	55.0M	54.3M	86.0M	119.9M	109.4M
Earnings from Cont. Ops	55.0M	54.3M	91.3M	127.4M	115.4M
Earnings from Discont. Ops	—	—	—	—	—
Bottom Line Net Income	55.0M	54.3M	86.0M	119.9M	109.4M
Per Share
Basic EPS	CN¥0.09	CN¥0.09	CN¥0.14	CN¥0.20	CN¥0.18
Diluted EPS	CN¥0.09	CN¥0.09	CN¥0.13	CN¥0.20	CN¥0.18
Revenue Per Share	CN¥1.26	CN¥1.27	CN¥1.49	CN¥1.64	CN¥1.59
Shares
Basic Shares Outstanding	593.2M	585.5M	593.8M	593.5M	593.5M
Diluted Shares Outstanding	593.2M	585.5M	593.8M	593.5M	593.5M
Profitability Metrics
EBITDA	—	158.1M	194.0M	226.4M	216.4M
D&A	—	98.4M	87.8M	82.5M	85.9M
EBIT	—	—	—	—	—

As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026